Aeglea BioTherapeutics competitors

Brian Lian is a CEO and President at Viking Therapeutics Inc; Board Member at Viking Therapeutics Inc; and Board Member at SEELOS THERAPEUTICS, INC. and is based in California, Kentucky. He has experience at OPPENHEIMER HOLDINGS INC and has worked as Senior Analyst at Fortis Financial Services, Mng Dir/Senior Research Analyst at SunTrust Robinson Humphrey, and Research Scientist at Amgen. Brian works or has worked as Senior Analyst at Fortis College. He attended University of Michigan, Indiana University, and Whitman College.

Gerrit joined Relypsa in October 2007 after negotiating the Relypsa spin out transaction from Amgen as an advisor to the lead investor 5AM Ventures. He co-founded Ilypsa in 2003 while at Symyx Technologies. Between 2003 and 2007, Gerrit held varying positions at Ilypsa and was in charge of the series A and B financings on the company side and licensing deals with Astellas and Cubist. As Ilypsa’s Chief Business Officer, Gerrit co-led the M&A negotiations and diligence efforts. Prior to Ilypsa, he joined Symyx in 1998 as a Staff Scientist, and was later promoted to Director of Business Development. Gerrit received his Ph.D. in polymer chemistry from the Max-Planck-Institute for Polymer Research in Mainz, Germany. He conducted postdoctoral research at Stanford University and the IBM Almaden Research Center.

New drugs that make a differenceSpecialties: Drug Discovery & Development;Accretion & Development of Biotech Talent;Research: Neuroendocrinology, Structural Pharmacology, Medicinal Chemistry, Reproductive Medicine, Endocrinology, Biophysics & Computational Chemistry, Receptor Pharmacology & Biology

• Member of the National Ernst and Young Entrepreneur of the Year Hall of Fame• Inducted into the University of Texas College of Natural Sciences Hall of Honor• Received Ohio University's School of Business Distinguished Business Award• Received Ohio University Konneker Medal, the highest award given to a faculty member or former student for entrepreneurial excellence• Named one of the top 10 Life Sciences CEOs in Texas by the Texas Healthcare and Bioscience InstituteMr. Hawkins is currently the President and CEO of Lumos Pharma, Inc. an early-stage orphan drug company based in Austin, Texas. He currently serves as a Board of Director for SciClone Pharmaceuticals Inc., a NASDAQ listed company (SCLN), a biopharmaceutical company whose lead product Zadaxin, an adjuvant for the influenza vaccine in immunocompromised patients or as an immune stimulant, has been approved in at least 13 countries.In addition he serves as a Board of Director for Cytori Therapeutics, Inc.; a global leader in stem cell research and the use of adipose derived stem and regenerative cells.Rick Hawkins is a member of the National Ernst and Young Entrepreneur of the Year Hall of Fame.Mr. Hawkins was inducted into the Hall of Honor for the College of Natural Sciences at the University of Texas by Dean, Mary Ann Rankin. In 2006 he received Ohio University’s Distinguished Business Achievement Award, and in 2014 was awarded the Konneker Medal, the leading entrepreneurial honor awarded by the University. Rick was named one the top 10 Life Sciences CEO’s in Texas by the Texas Healthcare & Bioscience Institute and was the keynote speaker at BioVenture Showcase 2008.

Louis Brenner, President and Chief Executive Officer of Allena Pharmaceuticals. Prior to joining Radius, he served as Senior Vice President at AMAG Pharmaceuticals, where he was responsible for the Phase 3 studies and the successful regulatory submission for Feraheme®. Before that, he served in progressively senior roles at Genzyme, where he advanced the development and commercialization of products to treat metabolic bone disease.He is the co-inventor of the formulation for Renvela®, an oral phosphate binder to treat hyperphosphatemia, and lead the acquisition of Bone Care International, manufacturer of Hectorol®, a synthetic Vitamin D analog for the treatment of hyperparathyroidism. He also previously served as a Director of PLC Medical Systems. Dr. Brenner is board-certified in Nephrology and cares for patients at Brigham and Women's Hospital in Boston, and is a lecturer in Medicine at Harvard Medical School. He received a BS in Biology from Yale University, an MD from Duke University, and an MBA from Harvard Business School.

David Arthur is a Chief Executive Officer at SALARIUS PHARMACEUTICALS, INC. and Board Member at SALARIUS PHARMACEUTICALS, INC. and is based in Wilton, Connecticut. He has worked as Managing Director at Dacon Pharma LLC, Process Improvement Engineer and Production Manager at Milliken & Co, and Business Development RTP N.C. at GSK. David studied at Fuqua School of Business between 1988 and 1990 and NC State University between 1980 and 1984.